The invention relates to substituted polycyclic aryl and heteroaryl
tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl
ester transfer protein (CETP; plasma lipid transfer protein-I) and
compounds, compositions and methods for treating atherosclerosis and other
coronary artery diseases. Preferred tertiary-heteroalkylamine compounds
are substituted N,N-disubstituted fused-heterocyclo amines. A preferred
specific N,N-disubstituted fused-heterocyclo amine is the compound:
##STR1##